<DOC>
	<DOCNO>NCT01338896</DOCNO>
	<brief_summary>The primary objective study compare adhesiveness two different patch formulation rotigotine use patch size 40 cm2 , assumption patch formulation show similar adhesiveness property .</brief_summary>
	<brief_title>Study Compare Adhesiveness Two Different Rotigotine Patch Formulations</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subjects diagnosis idiopathic ParkinsonÂ´s disease , continuous treatment commercially available rotigotine transdermal patch least 3 month , stable rotigotine dose include 8 mg/24 h patch least 2 week prior enrollment Subjects previously participate study , fail screen , participate another study investigational medicinal product ( IMP ) medical device within last 30 day currently participate Subject history significant skin hypersensitivity adhesive , transdermal product recently unsolved contact dermatitis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>Neupro</keyword>
</DOC>